WO1991008298A2 - Fusion proteins consisting of a ligand binding protein and a stable plasma protein - Google Patents
Fusion proteins consisting of a ligand binding protein and a stable plasma protein Download PDFInfo
- Publication number
- WO1991008298A2 WO1991008298A2 PCT/US1990/006849 US9006849W WO9108298A2 WO 1991008298 A2 WO1991008298 A2 WO 1991008298A2 US 9006849 W US9006849 W US 9006849W WO 9108298 A2 WO9108298 A2 WO 9108298A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- lhr
- ligand binding
- binding partner
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
Definitions
- the hybrid immunoglobulins are assembled as monomers, or hetero- or homo-multimers, and particularly as dimers or tetramers.
- these assembled immunoglobulins will have known unit structures as represented by the following diagrams.
- a basic four chain structural unit is the form in which IgG, IgD, and IgE exist.
- a four chain unit is repeated in the higher molecular weight immunoglobulins; IgM generally exists as a pentamer of basic four-chain units held together by disulfide bonds.
- IgA globulin, and occasionally IgG globulin may also exist in a multimeric form in serum. In the case of multimers, each four chain unit may be the same or different.
- the LHR extracellular domain generally is fused at its C-terminus to the immunoglobulin constant region.
- the precise site at which the fusion is made is not critical; other sites neighboring or within the extracellular region may be selected in order to optimize the secretion or binding characteristics of the soluble LHR-lg fusion. The optimal site will be determined by routine experimentation.
- the fusion may typically take the place of either or both the transmembrane and cytoplasmic domains.
- DNA encoding immunoglobulin light or heavy chain constant regions is known or readily available from cDNA libraries or is synthesized.
- immunoglobulin fusions may be made with fragments of the LHR, such as the complement binding domain, the carbohydrate domain, and the epidermal growth factor domain.
- the complement binding domain fusion finds usefulness in the diagnosis and treatment of complement-mediated diseases, as well as in the oligomerization of the fusion with the LHR or with other components on the lymphocyte surface.
- the resulting covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays of the LHR or for the preparation of anti-LHR antibodies for immunoaffinity purification of the recombinant LHR
- complete inactivation of the biological activity of the protein after reaction with ninhydrin would suggest that at least one arginyl or lysyl residue is critical for its activity, whereafter the individual residues which were modified under the conditions selected are identified by isolation of a peptide fragment containing the modified amino acid residue.
- modifications are within the ordinary skill in the art and are performed without undue experimentation.
- sodium borohydride suggested by Royer must be used at a high pH and has a significant tendency to reduce disulfide bonds.
- sodium cyanoborohydride which is effective at neutral pH and has very little tendency to reduce disulfide bonds is preferred.
- conjugates of this invention are separated from unreacted starting materials by gel filtration. Heterologous species of the conjugates are purified from one another in the same fashion.
- reverse-phase HPLC and chromatography using ligands for the hybrid immunoglobulin are useful for the purification of the hybrid.
- low concentrations (approximately 1-5 mM) of calcium ion may be present during purification.
- the LHR may preferably be purified in the presence of a protease inhibitor such as PMSF.
- Dephosphorylation refers to the removal of the terminal 5' phosphates by treatment with bacterial alkaline phosphatase (BAP). This procedure prevents the two restriction cleaved ends of a DNA fragment from "circularizing” or forming a closed loop that would impede insertion of another DNA fragment at the restriction site. Procedures and reagents for dephosphorylation are conventional. Maniatis, T. et al., Molecular Cloning pp. 133-134 (1982). Reactions using BAP are carried out in 50mM Tris at 68°C to suppress the activity of any exonucleases which are present in the enzyme preparations. Reactions are run for 1 hour. Following the reaction the DNA fragment is gel purified.
- BAP bacterial alkaline phosphatase
- Fig. 6 A shows that the most N-terminally localized motif of the LHR shows a high degree of homology with a number of calcium-dependent animal lectins, i.e., C-type lectins (1 ).
- C-type lectins include but are not limited to, various hepatic sugar binding proteins from chicken, rat, and human, soluble mannose-binding lectins, a lectin from Kupffer cells, the asialoglycoprotein receptor, a cartilage proteoglycan core protein, pulmonary surfactant apoproteins, and two invertebrate lectins from the flesh fly and acorn barnacle.
- cysteine residues In addition to 6 cysteine residues, virtually all members of this family share three glycine residues. The conservation of cysteine and glycine residues is consistent with the possibility of a structural role for this region in the LHR. It is believed that this domain may place the N-terminaliy localized carbohydrate binding region in an appropriate orientation for ligand interaction. It is further believed that this domain may serve to strengthen the interaction between the lymphocyte and endothelium by binding to an egf-receptor homologue on the endothelium surface.
- Proteins which encode a wide range of multiples of this repeated domain, include, among others, the human and murine complement H precursors, the human beta 2 glycoprotein, the Epstein Barr virus/C3d receptor, the human C4b binding protein, the decay accelerating factor, and the vaccinia virus secretory polypeptide.
- Figure 7C shows the homologies between the two direct repeats in the MLHR and the direct repeats found in proteins contained within the complement binding family. Many of the amino acids that are conserved in this class of complement binding proteins, including a number of conserved cysteine residues, are also found in the 2 repeats in this region of the MLHR.
- the two repeats contained within the MLHR are not only exact duplications of each other at the amino acid level, they also show exact homology at the nucleotide sequence level (nucleotide residues 685-865 and 866-1056). While it is possible that this result is due to a cloning artifact, a duplicated region has been found in a number of other clones isolated from a separate cDNA library produced from the MLHR expressing cell line, 38C13 (available from Stanford University, Palo Alto, California, U.S.A.), as well as in a human homologue of the MLHR (discussed, infra.).
- results of the PPME binding analysis are shown in Fig. 10.
- the lanes contain the following MLHR-lgG chimeras: A. Binding of PPME to MLHRL-, MLHRLE- and MLHRLEC-lgG chimeras. B. Inhibition of MLHRLEC-lgG-PPME binding with Mel 1 monoclonal antibody and EGTA. C. Inhibition of MLHRLEC-lgG-PPME binding with other carbohydrates.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69033705T DE69033705T3 (en) | 1989-11-22 | 1990-11-21 | HYBRID IMMUNOGLOBULINE |
DK99123412T DK1029870T3 (en) | 1989-11-22 | 1990-11-21 | Hybrid immunoglobulins for use in therapeutic methods |
EP91901202A EP0526452B2 (en) | 1989-11-22 | 1990-11-21 | Hybrid immunoglobulins |
DK91901202T DK0526452T4 (en) | 1989-11-22 | 1990-11-21 | hybrid immunoglobulin |
CA002072642A CA2072642C (en) | 1989-11-22 | 1990-11-21 | Fusion proteins consisting of a ligand binding protein and a stable plasma protein |
AT91901202T ATE199261T1 (en) | 1989-11-22 | 1990-11-21 | HYBRID IMMUNOLOBULINS |
HK98114595A HK1013298A1 (en) | 1989-11-22 | 1998-12-22 | Hybrid immunoglobulins |
GR20010400708T GR3035856T3 (en) | 1989-11-22 | 2001-05-11 | Hybrid immunoglobulins. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/440,625 US5116964A (en) | 1989-02-23 | 1989-11-22 | Hybrid immunoglobulins |
US440,625 | 1989-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991008298A2 true WO1991008298A2 (en) | 1991-06-13 |
WO1991008298A3 WO1991008298A3 (en) | 1991-10-17 |
Family
ID=23749509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006849 WO1991008298A2 (en) | 1989-11-22 | 1990-11-21 | Fusion proteins consisting of a ligand binding protein and a stable plasma protein |
Country Status (13)
Country | Link |
---|---|
US (1) | US5116964A (en) |
EP (3) | EP1970386A2 (en) |
JP (2) | JPH05503009A (en) |
AT (2) | ATE396735T1 (en) |
CA (1) | CA2072642C (en) |
DE (3) | DE69034253D1 (en) |
DK (2) | DK1029870T3 (en) |
ES (2) | ES2308826T3 (en) |
GR (1) | GR3035856T3 (en) |
HK (2) | HK1013298A1 (en) |
LU (1) | LU91498I2 (en) |
NL (1) | NL300372I1 (en) |
WO (1) | WO1991008298A2 (en) |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993022332A2 (en) * | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5455337A (en) * | 1991-09-18 | 1995-10-03 | Hoffmann-La Roche Inc. | DNA encoding chimeric polypeptides comprising the interleukin-5 receptor α-chain fused to immunoglobulin heavy chain constant regions |
WO1996008570A1 (en) * | 1994-09-14 | 1996-03-21 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US5917026A (en) * | 1996-02-05 | 1999-06-29 | Loewenadler; Bjoern | Fusion proteins of immunopotentiating activity |
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
WO2000027885A1 (en) * | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Novel chimeric polypeptide |
USRE36755E (en) * | 1989-09-05 | 2000-06-27 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US6201105B1 (en) | 1989-09-05 | 2001-03-13 | Craig A. Smith | Tumor necrosis factor receptor polypeptides recombinant P75 (Type II) |
US6306395B1 (en) | 1996-05-02 | 2001-10-23 | Mochida Pharmaceutical Co., Ltd. | Fas antigen derivatives |
WO2002018583A2 (en) | 2000-09-01 | 2002-03-07 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
US6399368B1 (en) | 1992-01-17 | 2002-06-04 | Board Of Regents, The University Of Texas System | Secretion of T cell receptor fragments from recombinant Escherichia coli cells |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
USRE38313E1 (en) | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
US6897294B2 (en) | 1996-05-07 | 2005-05-24 | Genentech, Inc. | Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
EP1619250A1 (en) | 1996-01-08 | 2006-01-25 | Genentech, Inc. | WSX receptor and ligands |
US7060278B2 (en) | 2001-08-29 | 2006-06-13 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
WO2006084327A1 (en) * | 2005-02-09 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
EP1714661A2 (en) | 2000-05-19 | 2006-10-25 | The Center for Blood Research, INC. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
US7183076B2 (en) | 1997-05-02 | 2007-02-27 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7432357B2 (en) | 2004-01-22 | 2008-10-07 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
US7511121B2 (en) | 2001-03-09 | 2009-03-31 | Arnason Barry G W | Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
US7794718B2 (en) | 2007-11-01 | 2010-09-14 | Perseid Therapeutics, LLC | Immunosuppressive polypeptides and nucleic acids |
EP2241622A2 (en) | 1994-03-18 | 2010-10-20 | Genentech, Inc. | Human trk receptors and their derivatives |
US7928072B2 (en) | 2004-09-13 | 2011-04-19 | Genzyme Corporation | Multimeric constructs |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
US8007813B2 (en) | 2003-03-26 | 2011-08-30 | Apogenix Gmbh | CD95-Fc fusion proteins |
US8163289B2 (en) | 2001-03-09 | 2012-04-24 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
US8163522B1 (en) | 1989-09-12 | 2012-04-24 | Hoffman-Laroche Inc. | Human TNF receptor |
US8178083B2 (en) | 2005-09-01 | 2012-05-15 | Ares Trading, S.A. | Treatment of optic neuritis |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
EP1144454B2 (en) † | 1998-10-23 | 2012-12-12 | Amgen Inc. | Modified peptides as therapeutic agents |
US8642745B2 (en) | 1997-05-02 | 2014-02-04 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US8907066B2 (en) | 2009-04-22 | 2014-12-09 | Merck Patent Gmbh | Antibody fusion proteins with a modified FcRn binding site |
US8926973B2 (en) | 2001-03-30 | 2015-01-06 | Merck Patent Gmbh | Reducing the immunogenicity of fusion proteins |
US9029330B2 (en) | 2005-12-30 | 2015-05-12 | Merck Patent Gmbh | Methods of treating cancer using interleukin-12p40 variants having improved stability |
US9066930B2 (en) | 2007-11-09 | 2015-06-30 | Genentech, Inc. | Activin receptor-like kinase-1 compositions and methods of use |
US9441029B2 (en) | 2010-08-06 | 2016-09-13 | Genzyme Corporation | VEGF antagonist compositions and uses thereof |
EP3141560A2 (en) | 2008-05-06 | 2017-03-15 | Genentech, Inc. | Affinity matured crig variants |
US9970944B2 (en) | 2004-02-17 | 2018-05-15 | Merck Sharp & Dohme Corp. | Methods of modulating cytokine activity; related reagents |
US10072092B2 (en) | 2005-12-30 | 2018-09-11 | Merck Patent Gmbh | Methods of use of anti-CD19 antibodies with reduced immunogenicity |
US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
Families Citing this family (556)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5750375A (en) * | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
US5242687A (en) * | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
US7264944B1 (en) | 1989-04-21 | 2007-09-04 | Amgen Inc. | TNF receptors, TNF binding proteins and DNAs coding for them |
ES2238070T3 (en) | 1989-04-21 | 2005-08-16 | Amgen Inc. | TNF RECEPTOR, TNF BINDING PROTEIN AND CODANT DNA FOR THESE. |
IL95031A (en) | 1989-07-18 | 2007-03-08 | Amgen Inc | Method for the production of a human recombinant tumor necrosis factor inhibitor |
US6143866A (en) * | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
US6267964B1 (en) * | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
DE4037837A1 (en) * | 1990-11-28 | 1992-06-04 | Behringwerke Ag | CELL-FREE RECEPTOR BINDING TESTS, THEIR PRODUCTION AND USE |
US7070991B2 (en) * | 1991-02-08 | 2006-07-04 | Progenics Pharmaceuticals, Inc. | Cells expressing a CD4-IgG2 chimeric heterotetramer |
AU660662B2 (en) | 1991-02-08 | 1995-07-06 | Progenics Pharmaceuticals, Inc. | CD4-gamma2 and CD4-IgG2 chimeras |
AU660981B2 (en) * | 1991-03-12 | 1995-07-13 | Astellas Us Llc | CD2-binding domain of lymphocyte function associated antigen 3 |
MX9203138A (en) * | 1991-03-12 | 1992-09-01 | Biogen Inc | DOMAIN OF LINK CD2-ANTIGEN 3 (LFA-3) ASSOCIATED WITH FUNCTION LYMPHOSITES. |
US20030206899A1 (en) * | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US5318890A (en) * | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6764681B2 (en) * | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
ATE242322T1 (en) * | 1992-03-30 | 2003-06-15 | Immunex Corp | FUSION PROTEIN CONTAINING TWO TUMOR NECROSIS FACTOR RECEPTORS |
US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
WO1994005314A1 (en) * | 1992-09-08 | 1994-03-17 | Centocor, Inc. | Peptide inhibitors of leukocyte adhesion |
WO1994006476A1 (en) * | 1992-09-15 | 1994-03-31 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
WO1994006456A1 (en) * | 1992-09-16 | 1994-03-31 | Genentech, Inc. | Protection against liver damage by hgf |
WO1994006469A1 (en) * | 1992-09-18 | 1994-03-31 | La Jolla Institute For Allergy And Immunology | Hiv fusion polypeptide |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
WO1994014836A1 (en) * | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
US5474766A (en) * | 1992-12-18 | 1995-12-12 | Washington University | Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator |
CA2153802A1 (en) * | 1993-01-25 | 1994-08-04 | Thomas F. Tedder | Chimeric selectins as simultaneous blocking agents for component selectin function |
US7534867B1 (en) | 1993-05-19 | 2009-05-19 | Schering Corporation | Purified mammalian Flt3 ligands; agonists; antagonists |
US6824779B1 (en) | 1993-07-26 | 2004-11-30 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting the interaction of B7-2 with its natural ligand |
US6084067A (en) * | 1993-07-26 | 2000-07-04 | Dana-Farber Cancer Institute | CTLA4/CD28 ligands and uses therefor |
US20050129670A1 (en) * | 1993-07-26 | 2005-06-16 | Genetics Institute, Llc. | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US6723705B1 (en) | 1993-08-19 | 2004-04-20 | Gentics Institute, Inc. | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US5861310A (en) * | 1993-11-03 | 1999-01-19 | Dana-Farber Cancer Institute | Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor |
US6130316A (en) * | 1993-07-26 | 2000-10-10 | Dana Farber Cancer Institute | Fusion proteins of novel CTLA4/CD28 ligands and uses therefore |
SE9302855D0 (en) * | 1993-09-06 | 1993-09-06 | Martin Lindberg | Method and means for producing plasma proteinase inhibitor binding proteins |
WO1995014787A1 (en) * | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
AU689214B2 (en) * | 1994-02-01 | 1998-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fusion proteins that include antibody and nonantibody portions |
US7294331B2 (en) * | 1994-03-07 | 2007-11-13 | Immunex Corporation | Methods of using flt3-ligand in hematopoietic cell transplantation |
PT749323E (en) * | 1994-03-08 | 2001-05-31 | Dana Farber Cancer Inst Inc | METHODS FOR MODULAR T-CELL ANERGY |
IL113484A0 (en) * | 1994-04-28 | 1995-07-31 | Immunex Corp | Viral proteins pharmaceutical compositions containing them their preparation and use |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US5814464A (en) * | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
JPH11501506A (en) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | Chimeric cytokines and their use |
US6410008B1 (en) * | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
US6808709B1 (en) * | 1994-12-30 | 2004-10-26 | The Regents Of The University Of California | Immunoglobulins containing protection proteins and their use |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US20030069196A1 (en) * | 1995-03-03 | 2003-04-10 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
US6455685B1 (en) | 1995-03-03 | 2002-09-24 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
US6211142B1 (en) * | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
CA2215394C (en) * | 1995-03-23 | 2011-04-26 | Immunex Corporation | Il-17 receptor |
US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
US20060193862A1 (en) * | 1995-03-30 | 2006-08-31 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
IL117645A (en) * | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US7175847B1 (en) * | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7153508B2 (en) * | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US7361330B2 (en) * | 1995-10-04 | 2008-04-22 | Immunex Corporation | Methods of using flt3-ligand in the treatment of fibrosarcoma |
US20020034517A1 (en) * | 1995-10-04 | 2002-03-21 | Kenneth Brasel | Dendritic cell stimulatory factor |
US7150992B1 (en) | 1995-10-04 | 2006-12-19 | Innunex Corporation | Methods of preparing dendritic cells with flt3-ligand and antigen |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US20030040467A1 (en) * | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US20030026779A1 (en) * | 1999-10-15 | 2003-02-06 | Liming Yu | Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
IL125552A0 (en) | 1996-02-09 | 1999-03-12 | Amgen Inc | Composition comprising interleukin-1 inhibitor and controlled release polymer |
NZ331539A (en) | 1996-02-20 | 2000-01-28 | Applied Research Systems | Hybrid proteins from two coexpressed receptors to form a heterodimer |
US6194177B1 (en) * | 1996-02-20 | 2001-02-27 | Applied Research Systems Ars Holding N.V. | DNA encoding a hybrid heterodimeric protein |
GB9604518D0 (en) * | 1996-03-02 | 1996-05-01 | Smithkline Beecham Plc | Novel compounds |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
US6015884A (en) | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6140305A (en) * | 1996-04-04 | 2000-10-31 | Bio-Rad Laboratories, Inc. | Hereditary hemochromatosis gene products |
US7026116B1 (en) * | 1996-04-04 | 2006-04-11 | Bio-Rad Laboratories, Inc. | Polymorphisms in the region of the human hemochromatosis gene |
US7063965B2 (en) * | 1996-04-05 | 2006-06-20 | Regeneron Pharmaceuticals, Inc. | Nucleic acid encoding TIE-2 ligand |
US6060054A (en) | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
US6117977A (en) * | 1996-04-24 | 2000-09-12 | Genentech, Inc. | Type C lectins |
US6451308B1 (en) * | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
WO1997041232A1 (en) * | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
US6849399B1 (en) | 1996-05-23 | 2005-02-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for diagnosis and treatment of iron misregulation diseases |
TW555765B (en) * | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
CA2257839C (en) * | 1996-07-12 | 2012-10-23 | Genentech, Inc. | Gamma-heregulin |
NZ333325A (en) * | 1996-07-12 | 2000-06-23 | Genentech Inc | Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors |
AU5696198A (en) | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
EP2002846B1 (en) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases |
AU737910B2 (en) * | 1997-01-31 | 2001-09-06 | Regents Of The University Of California, The | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7435793B2 (en) * | 1998-05-15 | 2008-10-14 | Genentech, Inc. | Peptides that induce chondrocyte redifferentiation |
ES2285768T5 (en) | 1997-04-16 | 2011-12-22 | Millennium Pharmaceuticals, Inc. | CRSP PROTEINS (SEGREGATED PROTEINS RICH IN CYSTEINE), NUCLEIC ACID MOLECULES CODING FOR THE SAME AND USE. |
US6190909B1 (en) * | 1997-04-17 | 2001-02-20 | Millennium Pharmaceuticals, Inc. | TH2-specific gene |
EP0980432A1 (en) * | 1997-05-01 | 2000-02-23 | Amgen, Inc. | Chimeric opg polypeptides |
US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
JP2002506438A (en) | 1997-06-13 | 2002-02-26 | プロジェニター,インコーポレーテッド | Methods and compositions for diagnosing and treating iron overload and iron deficiency |
US20020132253A1 (en) * | 1997-06-16 | 2002-09-19 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040191256A1 (en) * | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
KR100220645B1 (en) * | 1997-07-04 | 1999-09-15 | 구광시 | Process for producing benzene derivatives |
US6187564B1 (en) | 1997-07-10 | 2001-02-13 | Beth Israel Deaconess Medical Center | DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics |
US6242570B1 (en) | 1997-07-10 | 2001-06-05 | Beth Israel Deaconess Medical Center | Production and use of recombinant protein multimers with increased biological activity |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
US20030032103A1 (en) * | 1997-09-18 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6391311B1 (en) * | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
US6509173B1 (en) * | 1997-10-21 | 2003-01-21 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2 |
US6503184B1 (en) | 1997-10-21 | 2003-01-07 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
US20040136986A1 (en) * | 1997-10-31 | 2004-07-15 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6576743B1 (en) * | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
DK1037927T3 (en) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation |
US6207413B1 (en) * | 1998-01-22 | 2001-03-27 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding novel orphan cytokine receptors |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US7371836B2 (en) * | 1998-03-27 | 2008-05-13 | Genentech, Inc. | PRO526 nucleic acids |
US7723488B2 (en) * | 1998-03-27 | 2010-05-25 | Genentech, Inc. | Monoclonal antibodies to secreted and transmembrane polypeptides |
EP1071468B1 (en) * | 1998-04-15 | 2006-06-14 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
US7256039B2 (en) * | 1998-05-15 | 2007-08-14 | Genentech, Inc. | PRO4405 nucleic acids |
ES2292242T5 (en) * | 1998-05-15 | 2011-05-04 | Genentech, Inc. | THERAPEUTIC USES OF IL-17 HOMOLOGICAL POLYPEPTIDES. |
PT1086138E (en) | 1998-06-12 | 2010-01-04 | Genentech Inc | Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
AU775422B2 (en) * | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
US20070003545A9 (en) * | 1999-06-02 | 2007-01-04 | Eaton Dan L | Interleukin-8 homologous polypeptides and therapeutic uses thereof |
US7291712B2 (en) * | 1998-06-25 | 2007-11-06 | Genentech, Inc. | Interleukin-8 homologous polypeptides and therapeutic uses thereof |
US7339033B2 (en) * | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
US20020099197A1 (en) * | 1998-07-21 | 2002-07-25 | Rory A.J. Curtis | Novel potassium channel molecules and uses therefor |
WO2000012113A2 (en) * | 1998-08-31 | 2000-03-09 | Biogen, Inc. | Method of modulating memory effector t-cells using a cd2-binding agent, and compositions |
CN1329082C (en) * | 1998-10-16 | 2007-08-01 | 拜奥根Idec马萨诸塞公司 | Polymer conjugates of interferon beta-1a and their uses |
TR200101087T2 (en) * | 1998-10-16 | 2001-09-21 | Biogen, Inc. | Interferon beta-fusion proteins and their use |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
KR100719202B1 (en) | 1998-10-23 | 2007-05-16 | 키린-암젠 인코포레이티드 | A COMPOUND BINDING TO MPl RECEPTOR AND A PHARMACEUTICAL COMPOSITION THEREOF |
WO2000028035A1 (en) * | 1998-11-10 | 2000-05-18 | Human Genome Sciences Inc. | CHEMOKINE β-7 |
US7294482B2 (en) * | 1998-11-19 | 2007-11-13 | Millennium Pharmaceuticals, Inc. | EGF-like nucleic acids |
US7235642B1 (en) * | 1999-01-12 | 2007-06-26 | Genentech, Inc. | Anti-PRO 1313 antibodies |
WO2000056363A1 (en) | 1999-03-19 | 2000-09-28 | Genentech, Inc. | Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist |
US7011833B1 (en) * | 1999-05-06 | 2006-03-14 | Genetics Institute, Inc. | Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent |
US20050079577A1 (en) * | 1999-05-14 | 2005-04-14 | Ashkenazi Avi J. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1187852B1 (en) * | 1999-05-19 | 2007-08-08 | EMD Lexigen Research Center Corp. | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS |
IL146842A0 (en) * | 1999-06-01 | 2002-07-25 | Biogen Inc | Polymer conjugates of hedgehog proteins and uses |
WO2000073498A1 (en) * | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
US6924359B1 (en) | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
IL147269A0 (en) * | 1999-07-02 | 2002-08-14 | Genentech Inc | FVIIa ANTAGONISTS |
ATE330967T1 (en) | 1999-07-02 | 2006-07-15 | Genentech Inc | PEPTIDE COMPOUNDS BINDING TO HER2 |
WO2001004141A2 (en) * | 1999-07-12 | 2001-01-18 | Merck Patent Gmbh | Seripancrin |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
WO2001007084A1 (en) * | 1999-07-23 | 2001-02-01 | Regents Of The University Of California | Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery |
JP2003512303A (en) * | 1999-08-06 | 2003-04-02 | ジェネンテック・インコーポレーテッド | Peptide antagonists of factor VIIA |
PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
US20030166858A1 (en) * | 1999-09-16 | 2003-09-04 | Samuel Davis | TIE-2 ligands, methods of making and uses thereof |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
US7479539B1 (en) * | 1999-11-05 | 2009-01-20 | Curis, Inc. | Hedgehog fusion proteins |
EP1228214A2 (en) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
US7365157B2 (en) * | 1999-12-23 | 2008-04-29 | Genentech, Inc. | PRO9912 polypeptides |
US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
US7122632B2 (en) * | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
US20030153015A1 (en) * | 2000-01-20 | 2003-08-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
DE60122286T2 (en) * | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS |
CN1322897C (en) * | 2000-02-21 | 2007-06-27 | 应用研究系统Ars股份公司 | Use of IL-18 inhibitors |
US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US7572631B2 (en) * | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6984519B2 (en) | 2000-03-01 | 2006-01-10 | Genetech, Inc. | Nucleic acids encoding peptides that induce chondrocyte redifferentiation |
US20060073547A1 (en) * | 2000-03-01 | 2006-04-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20060002943A1 (en) * | 2000-03-02 | 2006-01-05 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US20020064820A1 (en) * | 2000-03-13 | 2002-05-30 | Jean-Michel Dayer | Apo-A-I regulation of T-cell signaling |
US7514239B2 (en) * | 2000-03-28 | 2009-04-07 | Amgen Inc. | Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof |
JP2003530108A (en) * | 2000-04-10 | 2003-10-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Cryptic-like secretory protein |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2747325A1 (en) * | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1286692A4 (en) * | 2000-04-25 | 2004-11-17 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2001083529A2 (en) * | 2000-04-28 | 2001-11-08 | Planet Biotechnology, Inc. | Immunoadhesin for the prevention of rhinovirus infection |
US20060015969A1 (en) * | 2000-04-28 | 2006-01-19 | Planet Biotechnology, Inc. | Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases |
EP1278778A2 (en) * | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modified peptides, comprising an fc domain, as therapeutic agents |
US20020102232A1 (en) * | 2000-05-11 | 2002-08-01 | Chang Tse W. | Compositions and methods for induction of active autoimmunity |
AU2001261585B2 (en) | 2000-05-12 | 2006-08-31 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US20050048614A1 (en) * | 2000-06-13 | 2005-03-03 | Children's Medical Center Corporation | Biosynthetic oncolytic molecules and uses therefor |
US20040034193A1 (en) * | 2001-06-13 | 2004-02-19 | Samy Ashkar | Biosynthetic oncolytic molecules and uses therefor |
US20030096339A1 (en) * | 2000-06-26 | 2003-05-22 | Sprecher Cindy A. | Cytokine receptor zcytor17 |
DK1325115T3 (en) * | 2000-06-26 | 2016-11-21 | Zymogenetics Inc | CYTOKINRECEPTOR ZCYTOR17 |
EP1320599A2 (en) | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
BR0112111A (en) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
UA81743C2 (en) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
CA2418950A1 (en) * | 2000-08-08 | 2002-02-14 | Zymogenetics, Inc. | Soluble zcytor 11 cytokine receptors |
US20030215916A1 (en) * | 2000-08-18 | 2003-11-20 | Feder John N. | Novel imidazoline receptor homologs |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
CA2422294C (en) * | 2000-09-14 | 2012-12-04 | Beth Israel Deaconess Medical Center, Inc. | Modulation of il-2- and il-15-mediated t cell responses |
JP2004517816A (en) | 2000-09-26 | 2004-06-17 | ジェネンテック・インコーポレーテッド | IGE receptor antagonist |
EP1320606A2 (en) * | 2000-09-29 | 2003-06-25 | Bristol-Myers Squibb Company | Identification and cloning of a full-length human cink-related gene, mist (mast cell immunoreceptor signal transducer) |
US20030211549A1 (en) * | 2000-10-06 | 2003-11-13 | Murphy Andrew J. | Functional proteins and therapeutic and diagnostic methods for use thereof |
JP2004528822A (en) * | 2000-11-07 | 2004-09-24 | ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | Methods and compositions relating to muscle-specific sarcomeric calcineurin binding protein (calsalcin) |
JP2004515479A (en) * | 2000-12-04 | 2004-05-27 | オークランド ユニサーヴィスィズ リミテッド | Immunomodulatory constructs and uses thereof |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
CA2436671C (en) | 2000-12-05 | 2015-02-03 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
US7056737B2 (en) * | 2001-02-16 | 2006-06-06 | Bristol-Myers Squibb Company | Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof |
CA2440221C (en) * | 2001-03-07 | 2013-02-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Expression technology for proteins containing a hybrid isotype antibody moiety |
EP2388590A1 (en) | 2001-04-02 | 2011-11-23 | Dana Farber Cancer Institute | PD-1, a receptor for B7-4, and uses thereof |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ITRE20010042A1 (en) * | 2001-04-24 | 2002-10-24 | Corghi Spa | LIFTING DEVICE FOR TIRE CHANGING MACHINES |
US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US7265208B2 (en) * | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
DE60239454D1 (en) * | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE |
BR0209546A (en) | 2001-05-11 | 2004-06-29 | Amgen Inc | Composition of matter, DNA, expression vector, host cell, and methods for treating B-cell mediated autoimmune disease, lupus, B-cell mediated cancer, and B-cell lymphoma |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP1478748A4 (en) * | 2001-06-15 | 2005-09-21 | Tanox Inc | Fce fusion proteins for treatment of allergy and asthma |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
CA2454618C (en) * | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
US7371371B2 (en) * | 2001-08-13 | 2008-05-13 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
AU2002323501C1 (en) * | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
AU2002332041A1 (en) * | 2001-10-05 | 2003-04-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
DK1446478T3 (en) * | 2001-10-19 | 2008-06-02 | Zymogenetics Inc | Dimerized growth factor as well as materials and processes for making them |
EP1446158B1 (en) * | 2001-10-25 | 2010-07-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Efficient inhibition of hiv-1 viral entry through a novel fusion protein including cd4 |
US20070118934A1 (en) * | 2001-10-26 | 2007-05-24 | Planet Biotechnology, Inc. | Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax |
US7737260B2 (en) | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Protein complex using an immunoglobulin fragment and method for the preparation thereof |
WO2003048334A2 (en) * | 2001-12-04 | 2003-06-12 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
JP2005527191A (en) * | 2001-12-18 | 2005-09-15 | アンドキューブ ソシエタ パー アクシオン シンプリフィー | Novel cell death-related proteins and THAP1 and PAR4 pathways in controlling apoptosis |
US7858297B2 (en) * | 2001-12-18 | 2010-12-28 | Centre National De La Recherche Scientifique Cnrs | Chemokine-binding protein and methods of use |
ES2425738T3 (en) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
EP1463752A4 (en) * | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | Albumin fusion proteins |
KR101271635B1 (en) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
KR100964411B1 (en) | 2002-01-18 | 2010-06-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | Polyalkylene glycol with moiety for conjugating biologically active compound |
JP4795641B2 (en) | 2002-01-18 | 2011-10-19 | ザイモジェネティクス, インコーポレイテッド | Novel cytokine zcytor17 ligand |
US7164002B2 (en) | 2002-02-06 | 2007-01-16 | Genentech, Inc. | FVIIa antagonists |
US20030211470A1 (en) * | 2002-03-15 | 2003-11-13 | Olson William C. | CD4-IgG2-based salvage therapy of HIV-1 infection |
CA2509767A1 (en) * | 2002-04-10 | 2003-10-16 | Applied Research Systems Ars Holding N.V. | Novel antagonists of mcp proteins |
US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
CN100562573C (en) | 2002-05-29 | 2009-11-25 | 雅玛山酱油株式会社 | New polyphosphate: amp phosphotransferase |
DE60334453D1 (en) * | 2002-05-30 | 2010-11-18 | Macrogenics Inc | CD16A BINDING PROTEINS AND USE FOR THE TREATMENT OF IMMUNE DISEASES |
NZ519371A (en) * | 2002-06-04 | 2004-11-26 | Auckland Uniservices Ltd | Immunomodulatory constructs and their uses |
EP1369128A1 (en) * | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
US7531178B2 (en) * | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
US20090130021A1 (en) * | 2002-06-07 | 2009-05-21 | Gotz Munch | Methods, products and uses involving platelets and/or the vasculature |
US20070071744A1 (en) * | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
PT1517921E (en) * | 2002-06-28 | 2006-09-29 | Domantis Ltd | DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM |
CN1241946C (en) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells |
WO2004006951A1 (en) * | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
AU2003251900B2 (en) | 2002-07-15 | 2008-12-18 | President And Fellows Of Harvard College | Methods and compositions for modulating T helper (Th) cell development and function |
US20040110681A1 (en) * | 2002-08-08 | 2004-06-10 | Xiao-Min Fan | Method to identify targeting molecules |
WO2004019866A2 (en) | 2002-08-28 | 2004-03-11 | Immunex Corporation | Compositions and methods for treating cardiovascular disease |
DE10251463A1 (en) * | 2002-11-05 | 2004-05-19 | BSH Bosch und Siemens Hausgeräte GmbH | Electrically-driven water circulation pump for automobile engine, ship, laundry machine or dish washing machine, with circulated liquid providing cooling of rotor of drive motor |
US20050054054A1 (en) * | 2002-11-12 | 2005-03-10 | Foss Francine M. | Interleukin-7 molecules with altered biological properties |
CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
JP2006523090A (en) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | Bispecific single domain antibody specific for ligand and for ligand receptor |
US20110223168A1 (en) * | 2002-12-27 | 2011-09-15 | Greg Winter | Ligand that has binding specificity for il-4 and/or il-13 |
GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP2272533A1 (en) * | 2003-01-13 | 2011-01-12 | MacroGenics, Inc. | Soluble FcyR fusion proteins and methods of use thereof |
EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Albumin fusion proteins |
CN1756767A (en) * | 2003-02-06 | 2006-04-05 | 诺和酶股份有限公司 | Human heavy chain antibody expression in filamentous fungi |
US20050096264A1 (en) * | 2003-02-25 | 2005-05-05 | Macdonald Lynn | Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones |
US20050142139A1 (en) * | 2003-03-21 | 2005-06-30 | Norbert Schulke | CD4-IgG2 formulations |
ATE475673T1 (en) * | 2003-03-24 | 2010-08-15 | Zymogenetics Inc | ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USE IN INFLAMMATION |
WO2004100882A2 (en) * | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Inhibition of drug binding to serum albumin |
WO2004101740A2 (en) | 2003-05-06 | 2004-11-25 | Syntonix Pharmaceuticals, Inc. | Clotting factor-fc chimeric proteins to treat hemophilia |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US8273347B2 (en) * | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
CA2525928A1 (en) | 2003-05-13 | 2005-01-06 | Depuy Spine, Inc. | A method of treating degenerative disc disease |
US7553827B2 (en) * | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US20040229878A1 (en) * | 2003-05-13 | 2004-11-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of P38 kinase |
PT1622939E (en) * | 2003-05-13 | 2012-03-28 | Merck Serono Sa | Active variants of the il-18 binding protein and medical uses thereof |
US7429378B2 (en) * | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7435808B2 (en) | 2003-06-25 | 2008-10-14 | Bristol-Myers Squibb Company | Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2 |
EP2221317A3 (en) * | 2003-06-30 | 2011-07-27 | Domantis Limited | PEGylated single domain antibodies (dAb) |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
EP3192872A1 (en) | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
UA89481C2 (en) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Human epo mimetic hinge core mimetibodies, compositions, methods and uses |
US20070274988A1 (en) * | 2003-10-10 | 2007-11-29 | Five Prime Therapeautics, Inc. | Kiaa0779, Splice Variants Thereof, and Methods of Their Use |
US20050239700A1 (en) * | 2003-10-14 | 2005-10-27 | Biogen Idec Inc. | Treatment of cancer using antibodies to LRRC15 |
WO2005042573A1 (en) * | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005063820A2 (en) * | 2003-12-30 | 2005-07-14 | Merck Patent Gmbh | Il-7 fusion proteins |
EP1699821B1 (en) * | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
EP1718329A4 (en) * | 2004-02-06 | 2008-09-10 | Astellas Us Llc | Methods of treating skin disorders |
US20100028995A1 (en) * | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
BRPI0509528A (en) * | 2004-03-31 | 2007-08-07 | Centocor Inc | human glp-1 imitation bodies, compositions, processes and uses |
US20080020383A1 (en) * | 2004-05-04 | 2008-01-24 | Genaissance Pharmaceuticals, Inc. | Haplotype Markers And Methods Of Using The Same To Determine Response To Treatment |
CA2565259A1 (en) * | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
US20060063208A1 (en) * | 2004-08-02 | 2006-03-23 | Woolf Clifford J | DRG11-responsive (DRAGON) gene and uses thereof |
US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
EP2324848A3 (en) * | 2004-10-21 | 2011-09-14 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
EP1812476B1 (en) | 2004-10-22 | 2010-07-21 | ZymoGenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
US20090311259A1 (en) * | 2004-11-17 | 2009-12-17 | Victoria Smith | Compositions and Methods for Treatment of Tumor of Hematopoietic Origin |
KR20070085886A (en) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | Il-7 variants with reduced immunogenicity |
CN100515491C (en) * | 2005-01-04 | 2009-07-22 | 健能隆医药技术(上海)有限公司 | Medical use of interleukin-22 |
KR20070100346A (en) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | Cripto binding molecules |
US8168588B2 (en) | 2005-01-25 | 2012-05-01 | Five Prime Therapeutics, Inc. | Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions |
KR100754667B1 (en) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same |
US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) * | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9296816B2 (en) * | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
PA8672101A1 (en) | 2005-04-29 | 2006-12-07 | Centocor Inc | ANTI-IL-6 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
WO2007143231A2 (en) * | 2006-01-10 | 2007-12-13 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists |
US7531637B2 (en) | 2005-05-06 | 2009-05-12 | Zymogenetics, Inc. | IL-31 monoclonal antibodies |
JP5150488B2 (en) | 2005-06-17 | 2013-02-20 | ワイス・エルエルシー | Method for purifying Fc region-containing protein |
CN101252951B (en) | 2005-06-30 | 2011-12-21 | 森托科尔公司 | Anti-IL-23 antibodies, compositions, methods and uses |
AU2006269458B2 (en) | 2005-07-08 | 2012-11-08 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
CN101443357A (en) * | 2005-08-12 | 2009-05-27 | 先灵公司 | MCP1 fusions |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
AU2006301846A1 (en) * | 2005-10-13 | 2007-04-19 | Akshaya Bio Inc. | Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response |
TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
KR20080082629A (en) * | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | Hepatocyte growth factor intron fusion proteins |
MY153249A (en) * | 2005-11-14 | 2015-01-29 | Rinat Neuroscience Corp | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
CA2632866A1 (en) * | 2005-12-01 | 2007-06-07 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
US20070161546A1 (en) * | 2005-12-15 | 2007-07-12 | Colm King | Methods and compositions for treatment of cancer |
JP2009521503A (en) * | 2005-12-22 | 2009-06-04 | ディー・エイチ・ワイ・アンド・カンパニー・リミテッド | Antibodies against interleukin-22 binding proteins and their use for the treatment of metabolic diseases |
HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-il-23 antibodies, compositions, methods and uses |
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
US20070179094A1 (en) | 2006-01-31 | 2007-08-02 | Bayer Schering Pharma Ag | Modulation of MDL-1 activity for treatment of inflammatory disease |
GB0604187D0 (en) * | 2006-03-02 | 2006-04-12 | Fusion Antibodies Ltd | Peptide and uses thereof |
WO2007115150A2 (en) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Binding partners with immunoglobulin domains modified to have extended half-life |
JP2009537605A (en) | 2006-05-24 | 2009-10-29 | メルク セローノ ソシエテ アノニム | Cladribine regimen for the treatment of multiple sclerosis |
NZ574093A (en) * | 2006-06-12 | 2011-03-31 | Symphogen As | Pan-cell surface receptor- specific therapeutics |
CA2656918A1 (en) * | 2006-06-22 | 2007-12-27 | Vaccinex, Inc. | Anti-c35 antibodies for treating cancer |
WO2008036449A2 (en) * | 2006-06-29 | 2008-03-27 | The Regents Of The University Of California | Chemical antibodies for immunotherapy and imaging |
EP2043603A4 (en) | 2006-07-11 | 2010-10-27 | Arubor Corp | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
US20080014285A1 (en) * | 2006-07-13 | 2008-01-17 | Di Mauro Thomas M | Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound |
LT2068889T (en) | 2006-08-10 | 2020-02-10 | Roy C. Levitt | Anakinra for use in the treatment of bronchiolitis obliterans syndrome |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
US20120282245A1 (en) | 2006-10-03 | 2012-11-08 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
US20080254512A1 (en) | 2006-11-02 | 2008-10-16 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
PE20081250A1 (en) * | 2006-11-28 | 2008-10-07 | Centelion | Fc FUSIONS WITH RECEIVER FOR MODIFIED SOLUBLE FGF, WITH IMPROVED BIOLOGICAL ACTIVITY |
CA2674140C (en) | 2007-01-05 | 2018-05-15 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
ES2464815T3 (en) | 2007-01-09 | 2014-06-04 | Biogen Idec Ma Inc. | SP35 antibodies and their uses |
CN104189885A (en) | 2007-02-23 | 2014-12-10 | 纽约哥伦比亚大学理事会 | METHODS TO ACTIVATE OR BLOCK THE HLA-E/Qa-1 RESTRICTED CD8+T CELL REGULATORY PATHWAY TO TREAT IMMUNOLOGICAL DISEASE |
CN101679934B (en) * | 2007-03-07 | 2014-04-02 | 格利科菲公司 | Production of glycoproteins with modified fucosylation |
DK2160401T3 (en) | 2007-05-11 | 2014-10-20 | Altor Bioscience Corp | Fusion Molecules and IL-15 Variants |
US7906149B2 (en) * | 2007-05-25 | 2011-03-15 | Boval Company, L.P. | Method for treating allergic dermatitis |
WO2008149354A2 (en) * | 2007-06-04 | 2008-12-11 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of inflammatory diseases and methods of using same |
CA2683801A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
BRPI0814465B1 (en) | 2007-07-26 | 2021-11-23 | Novagen Holding Corporation | FUSION PROTEIN, DIMER, METHOD FOR PRODUCING A FUSION PROTEIN, CELL LINEAGE, USES OF A FUSION PROTEIN AND A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION |
GB0717337D0 (en) * | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
AU2008310263B2 (en) | 2007-10-11 | 2014-09-11 | University Health Network | Modulation of SIRPALPHA - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
US20100278801A1 (en) * | 2007-10-16 | 2010-11-04 | Shepard H Michael | Compositions comprising optimized her1 and her3 multimers and methods of use thereof |
US8906356B2 (en) * | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
LT3002298T (en) | 2007-11-21 | 2019-12-10 | Univ Oregon Health & Science | Anti-factor xi monoclonal antibodies and methods of use thereof |
US20090312249A1 (en) * | 2007-12-06 | 2009-12-17 | Korea Advanced Institute Of Science And Technology | TLR4 decoy receptor protein |
BRPI0820099A2 (en) | 2007-12-07 | 2020-11-24 | Zymogenetics, Inc | isolated antibody or antibody fragment, pharmaceutical composition, and, use of an antibody or antibody fragment |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
NZ587292A (en) | 2008-03-04 | 2012-09-28 | Pfizer Ltd | Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat chronic pain |
MX2010010387A (en) | 2008-04-02 | 2010-10-15 | Macrogenics Inc | Bcr-complex-specific antibodies and methods of using same. |
PT2439212T (en) * | 2008-05-02 | 2017-03-29 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
US20110081347A1 (en) * | 2008-06-04 | 2011-04-07 | Macrogenics, Inc. | Antibodies with Altered Binding to FcRn and Methods of Using Same |
CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
AU2009274738B2 (en) | 2008-07-23 | 2012-12-13 | Hanmi Science Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
DK2370466T3 (en) | 2008-12-19 | 2015-08-03 | Univ Zuerich | Humane anti-alpha-synuclein-autoantistoffer |
US20100159485A1 (en) * | 2008-12-19 | 2010-06-24 | Centre For Dna Fingerprinting And Diagnostics | Detection of mycobacterium tuberculosis |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
EP2411412B1 (en) | 2009-03-24 | 2015-05-27 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against light and uses thereof |
CA2752908A1 (en) | 2009-04-01 | 2010-10-07 | Genentech, Inc. | Treatment of insulin-resistant disorders |
US10618964B2 (en) | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
SG174862A1 (en) | 2009-04-10 | 2011-11-28 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder |
KR101183262B1 (en) | 2009-04-22 | 2012-09-14 | (주)알테오젠 | Fusion protein or fusion peptide with increased half life by keeping long-acting activity, and method for increasing half life using the same |
EP3320920A1 (en) | 2009-05-08 | 2018-05-16 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
DK2429574T3 (en) | 2009-05-15 | 2015-06-22 | Univ Health Network | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGICAL CANCERS TARGETING THE SIRP-CD47 INTERACTION |
HUE025294T2 (en) * | 2009-06-15 | 2016-02-29 | Biokine Therapeutics Ltd | Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer |
US20110039300A1 (en) | 2009-08-10 | 2011-02-17 | Robert Bayer | Antibodies with enhanced adcc functions |
WO2011019622A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Cell culture methods to make antibodies with enhanced adcc function |
ES2912569T3 (en) * | 2009-08-28 | 2022-05-26 | Teva Pharmaceuticals Int Gmbh | Methods of treating visceral pain by administering antagonistic antibodies directed against calcitonin gene-related peptide |
EP2486141B1 (en) | 2009-10-07 | 2018-01-10 | MacroGenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
US20110165122A1 (en) * | 2009-11-10 | 2011-07-07 | The Regents Of The University Of California | Method for targeted and sustained antiviral therapy |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
US8637637B2 (en) | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
EP3295957B1 (en) | 2010-01-15 | 2019-08-07 | Kirin-Amgen, Inc. | Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis |
EP2536435B1 (en) | 2010-02-18 | 2017-11-15 | Janssen Biotech, Inc. | Monkey homolog of human interferon omega |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
NZ705128A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
CN103119054B (en) | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof |
US20110245469A1 (en) * | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives |
EP2558482B1 (en) | 2010-04-16 | 2017-09-27 | Janssen Biotech, Inc. | Engineered plant cysteine proteases and their uses |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
JP2013530187A (en) | 2010-06-17 | 2013-07-25 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treating inflammatory diseases. |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
CA2810217C (en) | 2010-09-02 | 2019-03-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
EP2918607B1 (en) | 2010-09-21 | 2017-11-08 | Altor BioScience Corporation | Multimeric il-15 soluble fusion molecules and methods of making and using same |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
EP2621950A4 (en) | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | Antibodies binding human collagen ii |
EA031698B1 (en) | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Human anti-tau antibodies |
US8883134B2 (en) * | 2010-10-20 | 2014-11-11 | Handok Pharmaceuticals, Inc. | Human interleukin-1 receptor antagonist—hybrid Fc fusion protein |
EP3214442A1 (en) | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a |
EP2638068B1 (en) | 2010-11-08 | 2018-12-26 | Novartis AG | Cxcr2 binding polypeptides |
CN103380145B (en) | 2010-12-17 | 2016-10-12 | 生物控股有限公司 | The mankind's anti-SOD1 antibody |
JP6189832B2 (en) | 2011-05-20 | 2017-08-30 | アルダーバイオ・ホールディングズ・エルエルシー | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute diarrhea |
US9745373B2 (en) | 2011-05-20 | 2017-08-29 | Alderbio Holdings Llc | Anti-CGRP compositions and use thereof |
CN103702685B (en) | 2011-05-20 | 2017-12-15 | 奥尔德生物控股有限责任公司 | Anti- CGRP antibody and antibody fragment are used to prevent or suppress photophobia in subject in need, especially migraineur or detest the purposes of light |
AU2012259162C1 (en) | 2011-05-21 | 2020-05-21 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use for extending serum half-life |
KR102046666B1 (en) | 2011-05-25 | 2019-11-19 | 이나뜨 파르마 | Anti-kir antibodies for the treatment of inflammatory disorders |
BR112013033258B1 (en) | 2011-06-23 | 2022-09-20 | University Of Zurich | ISOLATED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF WHICH BINDS ALPHASINUCLEIN, COMPOSITION AND ITS USES |
KR102103476B1 (en) | 2011-06-24 | 2020-04-23 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
MX2014000316A (en) * | 2011-07-08 | 2014-02-19 | Bayer Ip Gmbh | Fusion proteins releasing relaxin and uses thereof. |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
ES2888249T3 (en) * | 2011-10-11 | 2022-01-03 | Univ Zuerich | Combination drug comprising IL-12 and an agent for blocking T-cell inhibitory molecules for tumor therapy |
US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
MX342735B (en) | 2011-10-24 | 2016-10-07 | Halozyme Inc | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof. |
EP2802653A4 (en) | 2012-01-10 | 2015-09-02 | Univ Colorado Regents | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
JP6193275B2 (en) | 2012-03-02 | 2017-09-06 | ヴァクシネックス, インコーポレイテッド | Methods for treating B cell mediated inflammatory diseases |
CN104302177B (en) | 2012-05-17 | 2019-05-28 | 延伸生物科学股份有限公司 | Carrier for improved drug delivery |
EP2852610B1 (en) | 2012-05-23 | 2018-07-11 | Glykos Finland Oy | Production of fucosylated glycoproteins |
JP6285923B2 (en) | 2012-06-22 | 2018-02-28 | トラスティーズ・オブ・ダートマス・カレッジ | Novel VISTA-Ig constructs and use of VISTA-Ig for the treatment of autoimmune, allergic and inflammatory disorders |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2014011775A1 (en) | 2012-07-10 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Biomaterials for enhanced implant-host integration |
EP3613765A1 (en) | 2012-08-03 | 2020-02-26 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
CA2881966C (en) | 2012-08-24 | 2020-10-06 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
AU2013312211B2 (en) | 2012-09-07 | 2018-03-29 | King's College London | VISTA modulators for diagnosis and treatment of cancer |
WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
HUE058790T2 (en) | 2012-12-17 | 2022-09-28 | Pf Argentum Ip Holdings Llc | Treatment of cd47+ disease cells with sirp alpha-fc fusions |
EP2935326B1 (en) | 2012-12-21 | 2020-06-10 | Biogen MA Inc. | Human anti-tau antibodies |
EP3517545A1 (en) | 2012-12-31 | 2019-07-31 | Neurimmune Holding AG | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US20160002325A1 (en) | 2013-03-08 | 2016-01-07 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
AP2015008740A0 (en) | 2013-03-14 | 2015-09-30 | Macrogenics Inc | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
EP3460054B1 (en) | 2013-03-15 | 2020-10-21 | aTyr Pharma, Inc. | Histidyl-trna synthetase-fc conjugates |
SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
PE20151673A1 (en) | 2013-03-15 | 2015-11-27 | Genentech Inc | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE |
LT2981822T (en) | 2013-05-06 | 2020-12-28 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
US20160122829A1 (en) | 2013-06-06 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using PD-L1 Isoforms |
AR096891A1 (en) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
EP2840091A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2015085311A1 (en) | 2013-12-07 | 2015-06-11 | Case Western Reserve University | Compositions and methods of treating thrombosis |
WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
EP3087098B1 (en) | 2013-12-24 | 2020-04-08 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
EP3096776B1 (en) * | 2014-01-22 | 2020-12-02 | Antagonis Biotherapeutics GmbH | Novel glycosaminoglycan-antagonising fusion proteins and methods of using same |
IL247853B (en) | 2014-03-21 | 2022-08-01 | Teva Pharmaceuticals Int Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
KR20160130248A (en) | 2014-03-31 | 2016-11-10 | 키린-암젠, 인코포레이티드 | Methods of treating nail and scalp psoriasis |
CN107073109B (en) | 2014-06-11 | 2021-08-06 | 凯西·A·格林 | Use of VISTA agonists and antagonists to inhibit or enhance humoral immunity |
ES2899890T3 (en) | 2014-06-30 | 2022-03-15 | Altor Bioscience Corp | IL-15-based molecules and methods of using the same |
US10513724B2 (en) | 2014-07-21 | 2019-12-24 | Glykos Finland Oy | Production of glycoproteins with mammalian-like N-glycans in filamentous fungi |
EP3677285B1 (en) | 2014-08-04 | 2023-12-13 | Case Western Reserve University | Targeting peptides for detecting prostate cancer |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
BR112017006515A8 (en) | 2014-09-29 | 2018-02-27 | Univ Duke | bispecific molecules, compositions, method for treating or preventing HIV-1 infection in an individual with this need, and vector |
MY180054A (en) | 2014-09-30 | 2020-11-20 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
EP3209327A1 (en) | 2014-10-21 | 2017-08-30 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
JP6946182B2 (en) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc | Therapeutic Vitamin D Conjugate |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
EP3226900A4 (en) | 2014-12-05 | 2018-09-19 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
AU2015360903B2 (en) | 2014-12-08 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents |
JP2018506275A (en) | 2015-01-28 | 2018-03-08 | ジェネンテック, インコーポレイテッド | Gene expression markers and treatment of multiple sclerosis |
US11820807B2 (en) | 2015-06-12 | 2023-11-21 | Ubi Pharma Inc | Immunoglobulin fusion proteins and uses thereof |
WO2016207717A1 (en) | 2015-06-24 | 2016-12-29 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
IL294679B2 (en) | 2015-08-07 | 2023-10-01 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
KR20180042449A (en) | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T cell receptor (TCR) binding antibodies and uses thereof |
US11338065B2 (en) | 2015-10-08 | 2022-05-24 | Massachusetts Institute Of Technology | In situ expansion of engineered devices for regeneration |
US11207393B2 (en) | 2015-10-16 | 2021-12-28 | President And Fellows Of Harvard College | Regulatory T cell PD-1 modulation for regulating T cell effector immune responses |
US11129824B2 (en) | 2015-12-17 | 2021-09-28 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity and/or cancer cells growth |
US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
WO2017117558A1 (en) | 2015-12-31 | 2017-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications |
MX2018009800A (en) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anti-vista (b7h5) antibodies. |
SG11201807523PA (en) | 2016-03-10 | 2018-09-27 | Viela Bio Inc | Ilt7 binding molecules and methods of using the same |
CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
EP3442579A4 (en) | 2016-04-15 | 2019-12-18 | Immunext Inc. | Anti-human vista antibodies and use thereof |
KR102463844B1 (en) | 2016-05-27 | 2022-11-08 | 알토 바이오사이언스 코포레이션 | Construction and Characterization of Multimeric IL-15-Based Molecules with CD3 Binding Domains |
JP2018035137A (en) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | Novel anti-fibroblast activated protein (FAP) binding agent and use thereof |
CN109952314A (en) | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | Treat intractable migraine |
KR102392142B1 (en) | 2016-10-21 | 2022-04-28 | 알토 바이오사이언스 코포레이션 | Mutimeric IL-15-Based Molecules |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2018140121A1 (en) | 2017-01-30 | 2018-08-02 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis |
WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
KR20240038148A (en) | 2017-02-07 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
TW201842921A (en) | 2017-02-28 | 2018-12-16 | 法商賽諾菲公司 | Therapeutic rna |
US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
CA3216726A1 (en) | 2017-03-06 | 2018-09-13 | Altor Bioscience Corporation | Il-15-based fusions to il-12 and il-18 |
US20190048055A1 (en) | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
WO2018195338A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
BR112019023138A2 (en) | 2017-05-05 | 2020-07-28 | Vaccinex, Inc. | 4d human anti-semaphorin antibody |
WO2019046313A1 (en) | 2017-08-28 | 2019-03-07 | Altor Bioscience Llc | Il-15-based fusions to il-7 and il-21 |
CN112055595A (en) | 2018-01-22 | 2020-12-08 | 恩多塞特公司 | Methods of use of CAR T cells |
LT3743088T (en) | 2018-01-26 | 2022-12-27 | F. Hoffmann-La Roche Ag | Il-22 fc compositions and methods of use |
RU2020127792A (en) | 2018-01-26 | 2022-02-28 | Дженентек, Инк. | IL-22-Fc fusion proteins AND METHODS OF APPLICATION |
SG11202007694UA (en) | 2018-02-21 | 2020-09-29 | Genentech Inc | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
US11168138B2 (en) | 2018-03-26 | 2021-11-09 | Altor Bioscience, Llc | Anti-PDL1, IL-15 and TGF-beta receptor combination molecules |
KR102194644B1 (en) | 2018-04-26 | 2020-12-24 | 주식회사 굳티셀 | Novel fusion protein and pharmaceutical composition for preventing or treating cancer comprising the same |
CN112512547A (en) * | 2018-06-28 | 2021-03-16 | 国立大学法人冈山大学 | Neutrophil phagocytic power enhancer |
KR102263643B1 (en) | 2018-07-24 | 2021-06-10 | 주식회사 굳티셀 | A composition for preventing or treating immune related diseases |
CN110964116A (en) | 2018-09-26 | 2020-04-07 | 北京辅仁瑞辉生物医药研究院有限公司 | GLP1-Fc fusion proteins and conjugates thereof |
US11639380B2 (en) | 2019-01-08 | 2023-05-02 | H. Lundbeck A/S | Acute treatment and rapid treatment of headache using anti-CGRP antibodies |
WO2020148651A1 (en) | 2019-01-15 | 2020-07-23 | Janssen Biotech, Inc. | Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis |
MX2021008871A (en) | 2019-01-23 | 2021-08-19 | Janssen Biotech Inc | Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis. |
JP2022520088A (en) | 2019-02-13 | 2022-03-28 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Anti-peripheral lymph node addressin antibody and its use |
WO2020183270A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
KR20210142002A (en) | 2019-03-14 | 2021-11-23 | 얀센 바이오테크 인코포레이티드 | Methods of Preparation for Producing Anti-TNF Antibody Compositions |
CA3133388A1 (en) | 2019-03-14 | 2020-09-17 | Janssen Biotech, Inc. | Methods for producing anti-tnf antibody compositions |
KR20220009442A (en) | 2019-05-15 | 2022-01-24 | 아론바이오 리미티드 | Small molecules for cancer treatment, inhibition of chemokine activity and/or induction of cell death |
CN113874073A (en) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | Methods of treating inflammatory bowel disease with combination therapy of antibodies to IL-23 and TNF α |
CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
AU2020288404A1 (en) | 2019-06-03 | 2022-02-03 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis |
MA56015A (en) | 2019-06-03 | 2022-04-06 | Janssen Biotech Inc | ANTI-TNF ANTIBODY COMPOSITIONS AND METHODS FOR TREATING PSORIATIC ARTHRITIS |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
CA3174478A1 (en) | 2020-03-05 | 2021-09-10 | DiaMedica USA Inc. | Ulinastatin polypeptides |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
US20230227511A1 (en) * | 2020-05-14 | 2023-07-20 | Nippon Medical School Foundation | Therapeutic or preventive agent for infectious disease |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
KR20240032991A (en) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
IL309997A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Manufacturing methods for producing anti-tnf antibody compositions |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
WO2023168426A1 (en) | 2022-03-03 | 2023-09-07 | Enosi Therapeutics Corporation | Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof |
WO2023173084A1 (en) | 2022-03-11 | 2023-09-14 | University Of Rochester | Cyclopeptibodies and uses thereof |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0207402A2 (en) * | 1985-07-03 | 1987-01-07 | Bayer Ag | Process for producing proteins and polypeptides |
EP0271227A2 (en) * | 1986-11-12 | 1988-06-15 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and their use |
EP0288809A1 (en) * | 1987-04-16 | 1988-11-02 | Hoechst Aktiengesellschaft | Bifunctional proteins |
EP0294703A2 (en) * | 1987-06-10 | 1988-12-14 | Dana-Farber Cancer Institute, Inc. | Bifunctional antibody constructs and method for selectively destroying cell populations |
EP0308381A1 (en) * | 1987-09-14 | 1989-03-22 | Skandigen Ab | Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same |
EP0314317A1 (en) * | 1987-10-02 | 1989-05-03 | Genentech, Inc. | Adheson variants, nucleic acid encoding them and compositions comprising them |
EP0322094A1 (en) * | 1987-10-30 | 1989-06-28 | Delta Biotechnology Limited | N-terminal fragments of human serum albumin |
EP0325262A2 (en) * | 1988-01-22 | 1989-07-26 | The General Hospital Corporation | Cloned genes encoding IG-CD4 fusion proteins and the use thereof |
EP0325224A2 (en) * | 1988-01-22 | 1989-07-26 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs and biologically active peptide dimers. |
EP0346316A2 (en) * | 1988-06-10 | 1989-12-13 | KabiGen AB | Fusion protein and its use |
WO1990002338A1 (en) * | 1988-08-19 | 1990-03-08 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
WO1990005144A1 (en) * | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
EP0386906A1 (en) * | 1989-02-21 | 1990-09-12 | Dana-Farber Cancer Institute, Inc. | Lymphocyte-associated cell surface protein |
EP0391088A2 (en) * | 1989-03-16 | 1990-10-10 | Center For Blood Research Laboratories, Inc. | Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
EP0399666A1 (en) * | 1989-04-29 | 1990-11-28 | Delta Biotechnology Limited | Fusion proteins containing N-terminal fragments of human serum albumin |
WO1990014103A1 (en) * | 1989-05-17 | 1990-11-29 | Scripps Clinic And Research Foundation | Polypeptide-antibody conjugate for inhibiting cell adhesion |
WO1991000360A1 (en) * | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
EP0413622A1 (en) * | 1989-08-03 | 1991-02-20 | Rhone-Poulenc Sante | Albumin derivatives with therapeutic functions |
EP0414178A2 (en) * | 1989-08-23 | 1991-02-27 | The General Hospital Corporation | Non-human primate CD4 polypeptides and human CD4 molecules capable of being glycosylated |
WO1991004329A1 (en) * | 1989-09-20 | 1991-04-04 | Abbott Laboratories | Method of producing fusion proteins |
EP0125023B1 (en) * | 1983-04-08 | 1991-06-05 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
DE2247163A1 (en) | 1972-09-26 | 1974-03-28 | Merck Patent Gmbh | CARRIER MATRIX FOR FIXING BIOLOGICALLY ACTIVE SUBSTANCES AND THE PROCESS FOR THEIR PRODUCTION |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
GB1479268A (en) | 1973-07-05 | 1977-07-13 | Beecham Group Ltd | Pharmaceutical compositions |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
ATE12348T1 (en) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS. |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS5811808A (en) | 1981-07-16 | 1983-01-22 | Niles Parts Co Ltd | Azimuth detecting and displaying circuit |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4444878A (en) | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
DE3218121A1 (en) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Pharmaceutical compositions for tumour treatment |
JPS59125144A (en) | 1982-12-30 | 1984-07-19 | ソニー株式会社 | Digital signal transmitting system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
DE3483115D1 (en) | 1983-04-20 | 1990-10-11 | Youri Agabekov | ELECTRICAL INPUT RAIL. |
JPS60501277A (en) | 1983-05-09 | 1985-08-08 | ザ ゼネラル エレクトリツク カンパニ−,ピ−.エル.シ− | cathode ray tube display device |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US4745055A (en) | 1985-05-07 | 1988-05-17 | California Biotechnology Inc. | Fused protein for enzyme immunoassay system |
CA1340456C (en) | 1986-07-07 | 1999-03-23 | Hubert J.P. Schoemaker | Chimeric rodent/human immunoglobulins specific for tumor-associated antigens |
NO873164L (en) | 1986-07-30 | 1988-02-01 | Teijin Ltd | MUSEUM-HUMAN CHEMICAL ANTIBODIES. |
GB8623843D0 (en) | 1986-10-03 | 1987-10-21 | Airtech Ltd | Detection of unsafe voltages on mobile equipment |
GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
EP0308936B1 (en) * | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
GB8801756D0 (en) | 1988-01-27 | 1988-02-24 | Shell Int Research | Copolymer composition |
ES2176174T3 (en) | 1988-12-22 | 2002-12-01 | Genentech Inc | PROCEDURE FOR PREPARATION OF WATER SOLUBLE POLYPEPTIDES. |
-
1989
- 1989-11-22 US US07/440,625 patent/US5116964A/en not_active Expired - Lifetime
-
1990
- 1990-11-21 CA CA002072642A patent/CA2072642C/en not_active Expired - Lifetime
- 1990-11-21 DE DE69034253T patent/DE69034253D1/en not_active Expired - Lifetime
- 1990-11-21 DK DK99123412T patent/DK1029870T3/en active
- 1990-11-21 AT AT99123412T patent/ATE396735T1/en active
- 1990-11-21 DK DK91901202T patent/DK0526452T4/en active
- 1990-11-21 EP EP08005947A patent/EP1970386A2/en not_active Withdrawn
- 1990-11-21 ES ES99123412T patent/ES2308826T3/en not_active Expired - Lifetime
- 1990-11-21 DE DE69033705T patent/DE69033705T3/en not_active Expired - Lifetime
- 1990-11-21 ES ES91901202T patent/ES2155819T5/en not_active Expired - Lifetime
- 1990-11-21 WO PCT/US1990/006849 patent/WO1991008298A2/en active IP Right Grant
- 1990-11-21 DE DE122008000063C patent/DE122008000063I2/en active Active
- 1990-11-21 EP EP91901202A patent/EP0526452B2/en not_active Expired - Lifetime
- 1990-11-21 EP EP99123412A patent/EP1029870B1/en not_active Expired - Lifetime
- 1990-11-21 AT AT91901202T patent/ATE199261T1/en not_active IP Right Cessation
- 1990-11-21 JP JP3501520A patent/JPH05503009A/en not_active Withdrawn
-
1998
- 1998-12-22 HK HK98114595A patent/HK1013298A1/en not_active IP Right Cessation
- 1998-12-22 HK HK01101079A patent/HK1030222A1/en not_active IP Right Cessation
-
2001
- 2001-05-11 GR GR20010400708T patent/GR3035856T3/en unknown
-
2002
- 2002-02-04 JP JP2002026825A patent/JP2002325589A/en not_active Withdrawn
-
2008
- 2008-11-19 LU LU91498C patent/LU91498I2/en unknown
- 2008-11-27 NL NL300372C patent/NL300372I1/en unknown
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023B1 (en) * | 1983-04-08 | 1991-06-05 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, dna sequences, expression vectors and recombinant host cells therefor |
EP0207402A2 (en) * | 1985-07-03 | 1987-01-07 | Bayer Ag | Process for producing proteins and polypeptides |
EP0271227A2 (en) * | 1986-11-12 | 1988-06-15 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and their use |
EP0288809A1 (en) * | 1987-04-16 | 1988-11-02 | Hoechst Aktiengesellschaft | Bifunctional proteins |
EP0294703A2 (en) * | 1987-06-10 | 1988-12-14 | Dana-Farber Cancer Institute, Inc. | Bifunctional antibody constructs and method for selectively destroying cell populations |
EP0308381A1 (en) * | 1987-09-14 | 1989-03-22 | Skandigen Ab | Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same |
EP0314317A1 (en) * | 1987-10-02 | 1989-05-03 | Genentech, Inc. | Adheson variants, nucleic acid encoding them and compositions comprising them |
EP0322094A1 (en) * | 1987-10-30 | 1989-06-28 | Delta Biotechnology Limited | N-terminal fragments of human serum albumin |
EP0325262A2 (en) * | 1988-01-22 | 1989-07-26 | The General Hospital Corporation | Cloned genes encoding IG-CD4 fusion proteins and the use thereof |
EP0325224A2 (en) * | 1988-01-22 | 1989-07-26 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs and biologically active peptide dimers. |
EP0346316A2 (en) * | 1988-06-10 | 1989-12-13 | KabiGen AB | Fusion protein and its use |
WO1990002338A1 (en) * | 1988-08-19 | 1990-03-08 | The General Hospital Corporation | Recombinant hybrid immunoglobulin molecules and method of use |
WO1990005144A1 (en) * | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
EP0386906A1 (en) * | 1989-02-21 | 1990-09-12 | Dana-Farber Cancer Institute, Inc. | Lymphocyte-associated cell surface protein |
EP0391088A2 (en) * | 1989-03-16 | 1990-10-10 | Center For Blood Research Laboratories, Inc. | Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy |
EP0394827A1 (en) * | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
EP0399666A1 (en) * | 1989-04-29 | 1990-11-28 | Delta Biotechnology Limited | Fusion proteins containing N-terminal fragments of human serum albumin |
WO1990014103A1 (en) * | 1989-05-17 | 1990-11-29 | Scripps Clinic And Research Foundation | Polypeptide-antibody conjugate for inhibiting cell adhesion |
WO1991000360A1 (en) * | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
EP0413622A1 (en) * | 1989-08-03 | 1991-02-20 | Rhone-Poulenc Sante | Albumin derivatives with therapeutic functions |
EP0414178A2 (en) * | 1989-08-23 | 1991-02-27 | The General Hospital Corporation | Non-human primate CD4 polypeptides and human CD4 molecules capable of being glycosylated |
WO1991004329A1 (en) * | 1989-09-20 | 1991-04-04 | Abbott Laboratories | Method of producing fusion proteins |
Non-Patent Citations (8)
Title |
---|
Chemical Abstracts, volume 109, no. 25, 19 July 1988, (Columbus, Ohio, US), Reed, Roberta G. et al. : "Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin ", see page 587, abstract 227803g, & Clin. Chem. 1988, 34(10), 1992-1994 * |
J. Cell. Biochem. Suppl. 0 (14 part B), 1990, page 84, abstract CE217, S.R . Watson et al.: "Characterization and activities of murine peripheral lymph node homing receptor" * |
Letters to Nature, Vol. 339, May 1989 A. Traunecker et al.: "Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules ", page 68 - page 70 * |
Letters to Nature, Vol. 342, November 1989 D. Camerini et al.: "Leu-8/TQ1 is the human equivalent of the Mel-14 lymph node homing receptor ", page 78 - page 82 * |
Nature, Vol. 312, December 1984 M. S. Neuberger et al.: "Recombinant antibodies possessing novel effector functions ", page 604 - page 608 * |
Nature, Vol. 337, February 1989 D.J. Capon et al.: "Designing CD4 immunoadhesins for AIDS therapy ", page 525 - page 531 * |
Proc. Natl. Acad. Sci., Vol. 86, July 1989 M.H. Siegelman et al.: "Human homologue of mouse lymph node homing receptor: Evolutionary conservation at tandem cell interaction domains ", page 5562 - page 5566 * |
The Journal of Cell Biology, Vol. 109, July 1989 B.R. Bowen et al.: "Characterization of a human homologue of the murine peripheral lymph node homing receptor ", page 421 - page 427 * |
Cited By (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7057022B2 (en) | 1989-09-05 | 2006-06-06 | Immunex Corporation | Antibodies which specifically bind to TNF-R |
US7459528B2 (en) | 1989-09-05 | 2008-12-02 | Immunex Corporation | Glycoproteins which bind to TNF |
US6572852B2 (en) | 1989-09-05 | 2003-06-03 | Immunex Corporation | Method for suppressing inflammatory responses by administering TNFR |
US6201105B1 (en) | 1989-09-05 | 2001-03-13 | Craig A. Smith | Tumor necrosis factor receptor polypeptides recombinant P75 (Type II) |
US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
USRE36755E (en) * | 1989-09-05 | 2000-06-27 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
US8163522B1 (en) | 1989-09-12 | 2012-04-24 | Hoffman-Laroche Inc. | Human TNF receptor |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
US5712121A (en) * | 1991-09-18 | 1998-01-27 | Hoffmann-La Roche Inc. | Chimeric interleukin 5-receptor/immunoglobulin polypeptides |
US5668256A (en) * | 1991-09-18 | 1997-09-16 | Hoffmann-La Roche Inc. | Chimeric interleukin 5-receptor/immunoglobulin polypeptides |
US5455337A (en) * | 1991-09-18 | 1995-10-03 | Hoffmann-La Roche Inc. | DNA encoding chimeric polypeptides comprising the interleukin-5 receptor α-chain fused to immunoglobulin heavy chain constant regions |
US6623957B2 (en) | 1992-01-17 | 2003-09-23 | Board Of Regents University Of Texas System | Secretion of T cell receptor fragments from recombinant host cells |
US6399368B1 (en) | 1992-01-17 | 2002-06-04 | Board Of Regents, The University Of Texas System | Secretion of T cell receptor fragments from recombinant Escherichia coli cells |
WO1993022332A2 (en) * | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
WO1993022332A3 (en) * | 1992-04-24 | 1994-02-17 | Univ Texas | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
EP2241622A2 (en) | 1994-03-18 | 2010-10-20 | Genentech, Inc. | Human trk receptors and their derivatives |
USRE38313E1 (en) | 1994-05-06 | 2003-11-11 | Institut Gustave Roussy | Soluble polypeptide fractions of the LAG-3 protein, production method, therapeutic composition, anti-idiotype antibodies |
WO1996008570A1 (en) * | 1994-09-14 | 1996-03-21 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US7067129B2 (en) | 1995-01-17 | 2006-06-27 | The Brigham And Woman's Hospital, Inc. | Receptor specific transepithelial transport in therapeutics |
US7547436B2 (en) | 1995-01-17 | 2009-06-16 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US7060274B2 (en) | 1995-01-17 | 2006-06-13 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6030613A (en) * | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) * | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
EP1619250A1 (en) | 1996-01-08 | 2006-01-25 | Genentech, Inc. | WSX receptor and ligands |
US5917026A (en) * | 1996-02-05 | 1999-06-29 | Loewenadler; Bjoern | Fusion proteins of immunopotentiating activity |
US6306395B1 (en) | 1996-05-02 | 2001-10-23 | Mochida Pharmaceutical Co., Ltd. | Fas antigen derivatives |
US6953847B2 (en) | 1996-05-02 | 2005-10-11 | Mochida Pharmaceutical Co., Ltd. | Fas antigen derivative |
US6897294B2 (en) | 1996-05-07 | 2005-05-24 | Genentech, Inc. | Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
US8268313B2 (en) | 1996-05-07 | 2012-09-18 | Genentech, Inc. | Methods for using inhibitors of vascular endothelial growth factor activity |
EP2336322A1 (en) | 1996-05-07 | 2011-06-22 | Genentech, Inc. | Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
US9273113B2 (en) | 1996-05-07 | 2016-03-01 | Genentech, Inc. | Methods of inhibiting vascular endothelial growth factor activity |
US8268591B2 (en) | 1996-05-07 | 2012-09-18 | Genentech, Inc. | Compositions and methods for producing inhibitors of vascular endothelial growth factor activity |
US8273353B2 (en) | 1996-05-07 | 2012-09-25 | Genentech, Inc. | Inhibitors of vascular endothelial growth factor activity |
US7771721B2 (en) | 1996-05-07 | 2010-08-10 | Genentech, Inc. | Methods for using chimeric vascular endothelial growth factor receptor proteins |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
US8765412B2 (en) | 1997-05-02 | 2014-07-01 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US8642745B2 (en) | 1997-05-02 | 2014-02-04 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7183076B2 (en) | 1997-05-02 | 2007-02-27 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US9409989B2 (en) | 1997-05-02 | 2016-08-09 | Genetech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
EP1144454B2 (en) † | 1998-10-23 | 2012-12-12 | Amgen Inc. | Modified peptides as therapeutic agents |
WO2000027885A1 (en) * | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Novel chimeric polypeptide |
US6656728B1 (en) | 1999-02-08 | 2003-12-02 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
EP1714661A2 (en) | 2000-05-19 | 2006-10-25 | The Center for Blood Research, INC. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
WO2002018583A2 (en) | 2000-09-01 | 2002-03-07 | The Center For Blood Research, Inc. | Modified polypeptides stabilized in a desired conformation and methods for producing same |
US7897729B2 (en) | 2001-03-09 | 2011-03-01 | Iterative Therapeutics, Inc. | Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors |
US8986698B2 (en) | 2001-03-09 | 2015-03-24 | Iterative Therapeutics, Inc. | Method of using fusion proteins |
US7511121B2 (en) | 2001-03-09 | 2009-03-31 | Arnason Barry G W | Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
US9127063B2 (en) | 2001-03-09 | 2015-09-08 | Iterative Therapeutics, Inc. | Nucleic acids related to fusion proteins |
US8163289B2 (en) | 2001-03-09 | 2012-04-24 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
US8926973B2 (en) | 2001-03-30 | 2015-01-06 | Merck Patent Gmbh | Reducing the immunogenicity of fusion proteins |
EP2311960A2 (en) | 2001-08-29 | 2011-04-20 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
US7811984B2 (en) | 2001-08-29 | 2010-10-12 | Genentech, Inc. | BV8 nucleic acids and polypeptides with mitogenic activity |
US7060278B2 (en) | 2001-08-29 | 2006-06-13 | Genentech, Inc. | Bv8 nucleic acids and polypeptides with mitogenic activity |
EP2526960A1 (en) | 2003-03-12 | 2012-11-28 | Genentech, Inc. | Use of BV8 and/or EG-VEGF to promote hematopoiesis |
US8007813B2 (en) | 2003-03-26 | 2011-08-30 | Apogenix Gmbh | CD95-Fc fusion proteins |
US10017579B2 (en) | 2004-01-22 | 2018-07-10 | Meck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US8835606B2 (en) | 2004-01-22 | 2014-09-16 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US10633452B2 (en) | 2004-01-22 | 2020-04-28 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US9617349B2 (en) | 2004-01-22 | 2017-04-11 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US7432357B2 (en) | 2004-01-22 | 2008-10-07 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
US9970944B2 (en) | 2004-02-17 | 2018-05-15 | Merck Sharp & Dohme Corp. | Methods of modulating cytokine activity; related reagents |
US7928072B2 (en) | 2004-09-13 | 2011-04-19 | Genzyme Corporation | Multimeric constructs |
US9815892B2 (en) | 2004-09-13 | 2017-11-14 | Genzyme Corporation | Multimeric constructs |
US8658602B2 (en) | 2004-09-13 | 2014-02-25 | GenzymeCorporation | Multimeric constructs |
US7645861B2 (en) | 2004-09-24 | 2010-01-12 | Amgen Inc. | Modified Fc molecules |
US7655765B2 (en) | 2004-09-24 | 2010-02-02 | Amgen Inc. | Modified Fc molecules |
US7655764B2 (en) | 2004-09-24 | 2010-02-02 | Amgen Inc. | Modified Fc molecules |
US7662931B2 (en) | 2004-09-24 | 2010-02-16 | Amgen Inc. | Modified Fc molecules |
US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
WO2006084327A1 (en) * | 2005-02-09 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
US11266744B2 (en) | 2005-08-12 | 2022-03-08 | Amgen Inc. | Modified Fc molecules |
US8178083B2 (en) | 2005-09-01 | 2012-05-15 | Ares Trading, S.A. | Treatment of optic neuritis |
US9029330B2 (en) | 2005-12-30 | 2015-05-12 | Merck Patent Gmbh | Methods of treating cancer using interleukin-12p40 variants having improved stability |
US11208496B2 (en) | 2005-12-30 | 2021-12-28 | Cancer Research Technology Ltd. | Anti-CD19 antibodies with reduced immunogenicity |
US10072092B2 (en) | 2005-12-30 | 2018-09-11 | Merck Patent Gmbh | Methods of use of anti-CD19 antibodies with reduced immunogenicity |
US8268587B2 (en) | 2007-11-01 | 2012-09-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8491899B2 (en) | 2007-11-01 | 2013-07-23 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8445230B2 (en) | 2007-11-01 | 2013-05-21 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8318176B2 (en) | 2007-11-01 | 2012-11-27 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8283447B2 (en) | 2007-11-01 | 2012-10-09 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8496935B2 (en) | 2007-11-01 | 2013-07-30 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
US8071095B2 (en) | 2007-11-01 | 2011-12-06 | Perseid Therapeutics, LLC | Immunosuppressive polypeptides and nucleic acids |
US7794718B2 (en) | 2007-11-01 | 2010-09-14 | Perseid Therapeutics, LLC | Immunosuppressive polypeptides and nucleic acids |
US9066930B2 (en) | 2007-11-09 | 2015-06-30 | Genentech, Inc. | Activin receptor-like kinase-1 compositions and methods of use |
EP3141560A2 (en) | 2008-05-06 | 2017-03-15 | Genentech, Inc. | Affinity matured crig variants |
US8907066B2 (en) | 2009-04-22 | 2014-12-09 | Merck Patent Gmbh | Antibody fusion proteins with a modified FcRn binding site |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
US9441029B2 (en) | 2010-08-06 | 2016-09-13 | Genzyme Corporation | VEGF antagonist compositions and uses thereof |
US11780910B1 (en) | 2022-05-02 | 2023-10-10 | Novo Nordisk A/S | Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration |
Also Published As
Publication number | Publication date |
---|---|
EP1970386A2 (en) | 2008-09-17 |
DK1029870T3 (en) | 2008-09-29 |
ES2155819T5 (en) | 2007-09-16 |
HK1013298A1 (en) | 1999-08-20 |
EP0526452B1 (en) | 2001-02-21 |
ATE396735T1 (en) | 2008-06-15 |
DK0526452T4 (en) | 2007-05-07 |
DE69034253D1 (en) | 2008-07-10 |
ES2155819T3 (en) | 2001-06-01 |
CA2072642C (en) | 2002-07-23 |
DE69033705T3 (en) | 2007-07-12 |
DE69033705D1 (en) | 2001-03-29 |
EP0526452A1 (en) | 1993-02-10 |
ES2308826T3 (en) | 2008-12-01 |
DE122008000063I1 (en) | 2009-02-19 |
NL300372I1 (en) | 2009-02-02 |
WO1991008298A3 (en) | 1991-10-17 |
US5116964A (en) | 1992-05-26 |
EP1970386A8 (en) | 2009-07-08 |
DK0526452T3 (en) | 2001-06-18 |
EP1029870A2 (en) | 2000-08-23 |
DE122008000063I2 (en) | 2011-06-16 |
CA2072642A1 (en) | 1991-05-23 |
HK1030222A1 (en) | 2001-04-27 |
GR3035856T3 (en) | 2001-08-31 |
ATE199261T1 (en) | 2001-03-15 |
EP1029870A3 (en) | 2000-12-13 |
JP2002325589A (en) | 2002-11-12 |
EP1029870B1 (en) | 2008-05-28 |
DE69033705T2 (en) | 2001-08-02 |
LU91498I2 (en) | 2009-01-19 |
JPH05503009A (en) | 1993-05-27 |
EP0526452B2 (en) | 2007-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6406697B1 (en) | Hybrid immunoglobulins | |
US5514582A (en) | Recombinant DNA encoding hybrid immunoglobulins | |
US5116964A (en) | Hybrid immunoglobulins | |
US5098833A (en) | DNA sequence encoding a functional domain of a lymphocyte homing receptor | |
US5216131A (en) | Lymphocyte homing receptors | |
AU638964B2 (en) | Method for preparing water soluble polypeptides | |
EP2322228B1 (en) | T cell receptor fusion proteins and conjugates and methods of use thereof | |
EP0278776B2 (en) | Methods and deoxyribonucleic acid for the preparation of tissue factor protein | |
JP2003089654A (en) | Cd2-binding domain of lymphocyte function associated antigen 3 | |
AU2001275246A1 (en) | T cell receptor fusions and conjugates and methods of use thereof | |
CA2134756C (en) | Selectin variants | |
JP2009165489A (en) | Fusion protein composed of ligand bonded protein and stable plasma protein | |
JP3821858B2 (en) | Specific antibodies against activated platelets, their production, and their use in diagnosis and therapy | |
CA1341589C (en) | Methods and deoxyribonucleic acid for the preparation of tissue factor protein | |
CA2006475A1 (en) | Method for preparing water soluble polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
CFP | Corrected version of a pamphlet front page |
Free format text: TITLE REPLACED BY REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION,AND DRAWING ADDED |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2072642 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991901202 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991901202 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991901202 Country of ref document: EP |